Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common diabetes drug shield your brain after a stroke?

NCT ID NCT07241897

Disease control Sponsor: Second Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a diabetes drug called sentagliptin (a DPP4 inhibitor) can improve thinking and memory in people who have had a mild stroke and also have type 2 diabetes. About 312 participants will receive either the drug or a placebo daily for 180 days. Researchers will measure changes in cognitive tests to see if the drug reduces the risk of post-stroke cognitive impairment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sentagliptin Phosphate (a DPP4 inhibitor diabetes drug)
What this could lead to
If it works, this could point toward a new way to protect brain function after a stroke in people with diabetes.
What could go wrong
This is a Phase 3 trial, but it hasn't started yet. The drug may not improve cognition, and side effects from the medication are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 312 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Mild ischemic stroke, defined as a National Institutes of Health Stroke Scale (NIHSS) score ≤ 5. 2. Coexisting type 2 diabetes with a disease duration of less than 5 years. 3. Ability to complete the MoCA, MMSE, and the NINDS-CSN-recommended 1-hour standardized neuropsychological test for VCI. 4. Age between 40 and 75 years. 5. Onset of stroke within the last 2 weeks. 6. Glycated hemoglobin (HbA1c) between 6.5% and 8.5%. 7. More than 9 years of education. 8. Informed consent signed by the patient or their family. Exclusion Criteria: 1. Coexisting dementia or severe cognitive impairment (MoCA \< 17). 2. Coexisting severe depression, defined as a Hamilton Depression Rating Scale (HAMD) score ≥ 20. 3. Prior use of cognitive-enhancing drugs, such as donepezil or memantine. 4. Allergy to DPP4 inhibitors. 5. Past or current use of DPP4 inhibitors. 6. Past or current use of GLP-1 agonists. 7. Type 1 diabetes, latent autoimmune diabetes in adults, secondary diabetes, malignant tumors, autoimmune diseases, or other endocrine-related diseases. 8. Moderate or severe liver or kidney dysfunction. 9. Chronic or acute pancreatitis. 10. Pregnancy or lactation. 11. Severe infection or severely impaired immune response. 12. Participation in other clinical trials. 13. Past or current use of insulin therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabete mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus ischemic stroke type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabete mellitus Ischemic stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Neurology, Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, 215004, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.